drugset / Trial / NCT01469052
First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study was to characterize the safety of investigational agent AG-013736, in patients with solid tumors in this First In Human trial.
Timeline
- Start
- 2002-11
- Primary completion
- 2004-07
- Completion
- 2004-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axitinib | Small molecule | 5 mg | Oral |
| Subject | Axitinib | Small molecule | 10 mg | Oral |
| Subject | Axitinib | Small molecule | 15 mg | Oral |
| Subject | Axitinib | Small molecule | 20 mg | Oral |
| Subject | Axitinib | Small molecule | 30 mg | Oral |